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Abstract
Purpose: To report our experience on disease control and functional outcome using three modern combined-
modality approaches for definitive radiochemotherapy of locally advanced SCCHN with modern radiotherapy
techniques: radiochemotherapy (RChT), radioimmunotherapy (RIT) with cetuximab, or induction chemotherapy
with docetaxel, cisplatin, and 5-FU (TPF) combined with either RChT or RIT.
Methods: Toxicity and outcome was retrospectively analysed in patients receiving definitive RChT, RIT, or induction
chemotherapy followed by RChT or RIT between 2006 and 2009. Outcome was estimated using Kaplan-Meier
analyses, toxicity was analysed according to CTCAE v 3.0.
Results: Thirty-eight patients were treated with RChT, 38 patients with RIT, 16 patients received TPF followed by
either RChT or RIT. Radiotherapy was mostly applied as IMRT (68%). Long-term toxicity was low, only one case of
grad III dysphagia requiring oesophageal dilatation, no case of either xerostomia ≥ grade II or cervical plexopathy
were observed. Median overall survival (OS) was 25.7 months (RChT) and 27.7 months (RIT), median locoregional
progression-free survival (PFS) was not reached yet. Subgroup analysis showed no significant differences between
TPF, RChT, and RIT despite higher age and co-morbidities in the RIT group. Results suggested improved OS, distant
and overall PFS for the TPF regimen.
Conclusion: Late radiation effects in our cohort are rare. No significant differences in outcome between RChT and
RIT were observed. Adding TPF suggests improved progression-free and overall survival, impact of TPF on
locoregional PFS was marginal, therefore radiotherapeutic options for intensification of local treatment should be
explored.
Introduction
The past decade has seen major changes in the clinical
management of locally advanced squamous cell cancer
of the head and neck (SCCHN). Concomitant cytostatic
agents as well as major technical developments such as
intensity-modulated radiotherapy (IMRT) and image-
guided radiotherapy (IGRT) have changed standard
practice. Concomitant platin-based radiochemotherapy
has become one of the treatment standards [1-3];
however, improved outcome is bought at the cost of
increased toxicity when compared to radiotherapy alone.
Results comparable to concomitant radiochemotherapy
were achieved by the introduction of targeted therapies:
local control and overall survival rates were similar to
historic controls in a large phase III trial comparing
radioimmunotherapy with the monoclonal EGFR anti-
body cetuximab and radiation therapy only [4-6]. Inter-
estingly, combined radioimmunotherapy with cetuximab
did not show higher toxicity rates except for the typical
acneiforme skin rash. This agent can therefore also
be given to patients unable to tolerate the more toxic
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radiochemotherapy regimen. In the absence of direct or
prospective randomised comparisons between the stan-
dard cisplatin regimen and cetuximab in concomitant
chemoradiation, guidelines still recommend using stan-
dard regimen for patients fit enough to undergo che-
motherapy [7]. Two recent trials evaluating taxane-
based induction chemotherapy with docetaxel, cisplatin,
and 5-FU (TPF) [8,9] have raised the interest in induc-
tion chemotherapy for SCCHN. Both trials resulted in
an improvement of overall survival and progression-free
survival. Although manageable, the TPF regimen is
accompanied by sometimes marked toxicity and requires
experienced management.
While addition of either concomitant or sequential
chemotherapy regimen have been used to intensify
radiotherapy, technical possibilities have also evolved
within the past decade: intensity-modulated radiotherapy
(IMRT) has rapidly been adopted as a therapeutic stan-
dard in the treatment of head and neck cancer due to
high conformality and improved normal tissue sparing.
In particular, salivary gland sparing leads to improved
salivary gland function post radiotherapy and hence
significant reduction of xerostomia as compared to con-
ventional or three-dimensional techniques [10-13]. This
has recently been verified in a prospective phase III trial
comparing IMRT versus conventional techniques [14].
In a larger retrospective analysis, IMRT even lead to an
improvement in overall survival as compared to stan-
dard techniques [15].
Neither of the three combined treatment modalities
mentioned above have ever been directly compared in a
clinical trial nor has the use of modern radiotherapy
techniques in combination with these regimens ever
been evaluated prospectively. Hence, clinicians need to
rely on retrospective analyses and comparisons to evalu-
ate potential routine use. Therefore, we report our
experiences with the three regimens combined with
IMRT techniques in our daily clinical practice.
Patients and methods
Patients receiving definitive treatment for locally
advanced SCCHN between 01/2006 and 06/2009 were
identified retrospectively from our institutional database.
Baseline characteristics as well as treatment parameters
were retrieved from the hospital database in order to
evaluate efficacy and outcome of the various regimens
currently in use.
Only patients treated with a potentially curative intent
were included in our analysis. All patients were staged
prior to therapy with panendoscopy, CT of the head/
neck and chest, abdominal ultrasound, and bone scan.
Selection of specific combined regimen was based on
the patients’ overall performance status and co-morbid-
ities in our institutional interdisciplinary head and neck
tumour board. In cases of large tumour burden and
good overall performance score (ECOG 0 or 1), induc-
tion chemotherapy was evaluated. Treatment standard
at the time was combined chemoradiation according to
the Staar protocol [16]. RIT was indicated in cases
where concomitant chemoradiation was prohibitive due
to poor overall performance status (ECOG 2) or multi-
ple co-morbidities.
Radiation therapy: immobilisation/planning procedures
Patients were immobilized using either a combination of
individual scotch-cast mask and vacuum pillow or indi-
vidual thermoplastic head masks incl. shoulder fixation
(HeadStep®, ITV). Planning examinations included CT-
scan and contrast enhanced MRI for 3D image correla-
tion. Treatment isocentres were localised stereotactically
until 2008 and under image guidance (virtual simula-
tion) from 2008.
Radiation therapy: treatment
Target volumes were delineated in accordance with
current guidelines and recommendations [17-19]. RT
was prescribed to 66 - 72 Gy to the primary tumour/
involved nodes and between 54 - 57.6 Gy to the bilateral
neck. Intensity-modulated radiation therapy (IMRT) is
the treatment of choice for all patients, 3D and conven-
tional techniques were only used in patients unable to
tolerate longer treatment times (IMRT: approx. 15-20
min) per fraction. Only patients in severely reduced per-
formance state received 2D radiation, therefore use of
the classical concomitant boost concept was prohibitive.
The median dose to the contralateral parotid was below
27 Gy; if possible, also the ipsilateral parotid gland was
spared. Maximum doses to the spinal cord were limited
to < 40 Gy. IMRT treatment was either carried out at a
6 MV linac in step-and-shoot technique or at a 6 MV
tomotherapy unit.
Patient position was verified at least weekly using CT-
control scans, MV cone-beam CT, and portal images.
Radiochemotherapy with carboplatin/5-FU
According to our institutional protocols, patients with
locally advanced SCCHN are treated with carboplatin
and 5-FU according to the protocol published by Staar
et al. [16].
Carboplatin is given at 70 mg/m2 as one-hour infusion
and 5-FU as 600 mg/m2 (23 h) on days 1 to 5 and days
29 to 33 of radiation. Patients are provided with stan-
dard antiemetic prophylaxis and hydration.
Radioimmunotherapy with cetuximab
After administration of anti-histamines and corticoster-
oids, the monoclonal antibody cetuximab (Erbitux®) was
administered at 400 mg/m2 body surface loading dose
seven days prior to RT-treatment start. Weekly adminis-
trations of cetuximab at 250 mg/m2 body surface fol-
lowed for the duration of radiotherapy according to
general recommendations of the vendor.
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Induction chemotherapy with TPF
Patients received induction chemotherapy with docetaxel/
cisplatin/5-FU (TPF) according to the schedule described
by Vermorken et al. [9] and to standard recommenda-
tions of the vendors. In addition, patients received pro-
phylactic antibiotic treatment, usually consisting of
ciprofloxacine 500 mg po bid for 10 days starting one
week after commencement of each cycle. G-CSFs were
administered as indicated. The first re-staging was carried
out after the second cycle by either CT or MRI.
Analysis
Treatment response was analysed 6 weeks post comple-
tion of radiotherapy (1st f/u) and 3 months thereafter
(2nd f/u) based on available diagnostic imaging (CT or
MRI) and clinical examinations according to RECIST
criteria [20]. Treatment outcome/survival rates were
evaluated using higher non-parametric statistics
(Kaplan-Meier survival analysis [21]/log-rank and Wil-
coxon test). Progression-free survival was defined as the
time from start of radiation therapy until first event (i.e.
locoregional relapse, distant metastases, death). Simi-
larly, overall survival was calculated from start of radio-
therapy until death from any cause. To test for
differences between the treatment groups, a student-t
test or Fisher’s exact-test were used where appropriate.
Statistics were carried out using the Addinsoft xlstat life
2011© software package. Toxicity was evaluated based
on recorded clinical examinations and documentation
within the individual patient charts and assessed using
NCI CTC v 3.0.
Results
After exclusion of patients with nasal or paranasal sinus
cancers, partial resections, and re-irradiations, 76
patients receiving primary radiotherapy for locally
advanced carcinoma of the head and neck between 01/
2006 and 06/2009 were identified. Thirty-eight patients
received primary radiochemotherapy (RChT), 38
patients radioimmunotherapy (RIT) with the EGFR-inhi-
bitor cetuximab. The cohort included 16 patients receiv-
ing upfront induction chemotherapy with docetaxel,
cisplatin, and 5-FU (TPF) before either radiochemother-
apy (10 pts) or radioimmunotherapy (6 pts).
Patient baseline characteristics, treatment sites, and
stages are displayed in table 1. All patients received irra-
diation to bilateral nodal levels (levels II-V), most
patients were treated by IMRT (30/38 pts in the RChT
group, 22/38 pts in the RIT group), median doses to the
primary and involved nodes were 68.2 Gy (RChT) and
66 Gy (RIT) (table 2). Thirty-seven out of 38 patients in
the RChT group and 34/38 patients in the RIT group
completed their treatment as scheduled. One patient in
the RChT group discontinued therapy due to progres-
sive renal failure, three patients in the RIT group
declined further therapy. Thirty-four patients have
deceased as of January 2011. Median follow-up in the
RChT cohort is 18.7 months [0.63 - 51.3 months] com-
pared with 10.8 months [0.2 - 76.2] in the RIT cohort.
Median overall survival (Figure 1) in the entire RChT
cohort (n = 38) was 25.7 months and 27.7 months in
the entire RIT group (n = 38). Median locoregional pro-
gression-free survival (Figure 2) was not reached in
either of the groups. Neither overall nor locoregional
progression-free survival differed significantly between
the two groups.
Patients treated with induction chemotherapy followed
by either RChT or RIT (n = 16), RChT (n = 28), and RIT
(n = 32) were analysed separately (Figures 3, 4, 5, 6).
Overall and progression-free survival again was not
significantly different between the three treatment
groups although the TPF-group was trending towards
improved overall survival (Figure 3), distant PFS (Figure
4) and overall PFS (Figure 5). No significant differences
could be observed regarding locoregional PFS (Figure 6).
Radiochemotherapy and radioimmunotherapy following
TPF induction were compared but neither survival nor
local control differed significantly (data not shown)
therefore, analysis within one group seems justified.
Toxicity was within the expected range (table 3),
mucositis being the most common side-effect and gra-
dually resolving up to the first follow-up 6 weeks post
treatment. 48 patients had a PEG tube insertion, 4
patients a central venous catheter. Acute dysphagia rates
were 35.5% (27 pts, RChT) and 32.9% (25 pts, RIT).
Dysphagia gradually resolved with time, late swallow-
ing dysfunction was observed in 2 patients in the RChT
group, one of them needing oesophageal dilatation 2
years post completion of treatment. Two patients in the
RChT group developed aspiration pneumonia.
Although 9 patients a priori had impaired salivary
gland function documented by salivary flow scintigraphy
before treatment start, only 2 patients complained of
mild xerostomia beyond the 2nd follow-up. There was
no case of CTC grade II xerostomia. Despite high radia-
tion doses given in the proximity of the brachial plexus
due to cervical lymph node metastases, no cervical
plexopathy was observed.
Six of 76 patients underwent salvage surgery for locor-
egional relapse, 3 patients were treated by laryngectomy
(RChT: 2 pts, RIT 1 pt), 1 patient by partial glossectomy
(RChT) and 3 patients (RChT) received salvage neck
dissection, therefore the overall organ preservation rate
in this cohort is 96.1%.
Discussion
Side-effects of the two principal treatment regimens
RChT and RIT were within the expected range. As
expected, acute side-effects were slightly higher in the
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chemoradiation group though not statistically signifi-
cant. Overall late toxicities were mild: we observed only
one case of CTC grade III late dysphagia requiring treat-
ment by upper oesophageal dilatation. Following this
procedure, the patient patient’s symptoms have resolved.
No other higher-grade (CTC ≥°II) swallowing dysfunc-
tion was recorded. However, one of the major limita-
tions in the evaluation of swallowing dysfunction in our
patients is the fact that swallowing function was not
evaluated prospectively. Therefore initial swallowing
function tests are not available for most of the patients.
Evaluation was carried out on documented ENT follow-
up examinations, which mostly consisted of clinical and
endoscopical examination post therapy. Hence the rate
of silent aspirations in our patients may presumably be
higher than the actual rates reported here [22-25].
Nevertheless, most patients did not experience compli-
cations nor have they subjectively reported swallowing
problems. Regarding the initially very advanced tumour
stages, this encouraging fact may be attributed to our
routine use of IMRT [24,25].
Survival as well as control rates are consistent with
results from previously reported trials [16,4,26-30]. Locor-
egional control at one year between 49% (RChT) and
56.7% (RIT) was slightly lower than outcome reported in
the RTOG 99-14 trial [27] using altered fractionation in
addition to chemoradiation but comparable to the results
reported by Staar et al [16]. The results for local control
Table 1 Patient baseline characteristics and demographics
radiochemotherapy radioimmunotherapy TPF induction
site pts, (%)
hypopharynx 17 (44.7) 3 (7.9) 5 (31.3)
oropharynx 7 (18.4) 6 (15.8) 3 (18.8)
base of tongur 5 (13.2) 4 (10.5) 1 (6.3)
oral cavity 4 (10.5) 12 (31.6) 1 (6.3)
oro-/hypopharynx 3 (7.9) 5 (13.2) 3 (18.8)
larynx 1 (2.6) 7 (18.4) 1 (6.3)
oropharynx+hypopharynx 1 (2.6) 1 (6.3)
lip 1 (2.6)
stage T1 1 (2.6) 6 (15.8)
T2 3 (7.9) 6 (15.8) 1 (6.3)
T3 4 (10.5) 4 (10.5) 2 (12.5)
T4 30 (78.9) 22 (57.9) 13 (81.3)
N0 3 (7.9) 10 (26.3) 1 (6.3)
N1 2 (5.3) 4 (10.5) 2 (12.5)
N2a 3 (7.9)
N2b 5 (13.2) 6 (15.8) 4 (25)
N2c 23 (60.5) 15 (39.5) 8 (50)
N3 4 (10.5) 1 (6.3)
pN2b 1 (2.6)
M1 2 (5.3) 4 (10.5) 0
primary treatment 35 (92.1) 26 (68.4) 15 (93.8)
local relapse 3 (7.9) 12 (31.6) 1 (6.3)
seconday tumours 2 (5.3) 2 (5.3) 2 (12.5)
Total 38 38 16
age [a] median 61.1 71.4 60.3
range 17 - 74 50 - 85 17 - 68
p < 0.001 p < 0.001
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rates are also in the range reported by Bonner et al [4,5]
despite the high rates of T4 tumours both in our RChT
and RIT group and despite the selection bias in the RIT
group. All our RIT patients had a very limited to poor
pre-therapeutic performance status and most were also
elderly patients. Demonstrated by Cooper et al [31] and
more recently by Agarwal and Siddiqui et al. [32,33] one
of the most important predictive factors for patient
outcome are tumour and nodal stage as well as initial
performance status [34] and advanced age. Hence, our
radioimmunotherapy patients in fact represent a very
negative pre-selection with a combination of adverse
prognostic factors not represented in prospective and/or
randomised clinical trials. In the Bonner trial [4], such
patients were shown to benefit less than younger, fitter
patients.
Even more remarkable is the fact that neither survival
nor locoregional control rates differed significantly
between radiochemotherapy and and radioimmunother-
apy in our cohorts further supporting data from retro-
spective comparisons by Caudell et al. [4,6]. Overall
survival rates (at 2 years: 48.7% (RChT), 79.3% (TPF),
50.0% (RIT) are even slightly higher than in our refer-
ence trial [16] despite the fact that also older patients
and patients with limited pulmonary metastases were
included in our analysis. In addition, more patients in
the RIT group discontinued treatment due to worsening
of overall condition.
Table 2 Treatment characteristics
radiochemotherapy radioimmunotherapy
treatment pts
primary radiochemotherapy 28 32




regular completion of treatment 37 34
dose (median; [Gy]) primary/involved nodes 68.2 66
range 22 - 72 16 - 70.6
neck 56 55.8
range 49.8 - 60 16 - 60
Figure 1 Overall survival. 1: RChT; 2: RIT. RChT (n = 38), RIT
(n = 38). RChT OS @ 2 years: 58.9%. RIT OS @ 2 years: 52.7%.
Log-rank/Wilcoxon ns.
Figure 2 Locoregional progression-free survival. 1: RChT; 2: RIT.
RChT (n = 38), RIT (n = 38). RChT @ 2 years: 53.7%. RIT @ 2 years:
60.0%. Log-rank/Wilcoxon ns.
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For overall progression-free survival, distant progres-
sion-free survival, and overall survival, TPF induction
showed a visible trend towards improved outcome inde-
pendent of the subsequent treatment modality (RChT or
RIT), although this trend did not reach statistical signifi-
cance. This is in line with a randomized phase III trial
presented by Hitt et al at at ASCO 2009 [35]. It cannot
be excluded that age and performance state of the
patients receiving TPF has caused parts of the improve-
ment in progression-free and overall survival. While this
may be true, our data also shows that improvement of
survival rates beyond the results reported in the large
radiochemotherapy trials is possible in carefully selected
patients and can hence be an option in the hands of
experienced oncologists.
The benefit in locoregional progression-free survival -
though not statistically significant - seems to be only
slightly higher for the TPF group. Also patient numbers
are small, this may suggest induction chemotherapy with
TPF influences progression-free survival selectively by
reduction of distant metastases rather than improvement
of local control, which is supported by the TAX 323 and
Figure 3 Overall survival. 0: RChT; 1: TPF; 2: RIT. RChT median:
22.8 months [95%-CI: 13.1 - 40.9]; OS @ 2 years: 48.7%. TPF median:
not reached; OS @ 2 years: 79.3%. RIT median: 27.7 months [95%-CI:
12.6 - 33.9]; OS @ 2 years: 50%. RChT vs TPF: logrank 0.05, Wilcoxon
0.067. RChT vs RIT: ns. RIT vs TPF: ns.
Figure 4 Distant PFS. 0: RChT; 1: TPF; 2: RIT. RChT: @ 2 years:
55.1%. TPF: @ 2 years: 76.9%. RIT: @ 2 years: 60.2%. RChT vs TPF,
RChT vs RIT, RIT vs TPF: ns.
Figure 5 Overall PFS. 0: RChT; 1: TPF; 2: RIT. RChT median: 10.9
months [95%-CI: 8.3 - 33.7]; PFS @ 2 years: 34.7%. TPF: PFS @ 2
years: 66.6%. RIT median: 15.6 months [95%-CI: 7.1 - 33.9]; PFS @ 2a:
34.5%. RChT vs TPF, RChT vs RIT, RIT vs TPF: ns.
Figure 6 Locoregional PFS. 0: RChT; 1: TPF; 2: RIT. RChT median
23.8 months [95%-CI: 10.2 - 33.7]; locoregional PFS @ 2 years: 49.0%.
TPF: @ 2 years: 71.4%. RIT: @ 2 years: 56.7%. RChT vs TPF, RChT vs
RIT, RIT vs TPF: ns.
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324 trials [8,9]. Further analysis of our patients treated
with TPF followed by radiochemotherapy or radioimmu-
notherapy revealed no significant difference between
RChT and RIT following TPF. The number of patients
treated with this regimen at our institution though, is still
small. So far, TPF followed by RIT could be favoured due
to lower accompanying toxicity and potentially higher
patient compliance. The TREMPLIN trial addresses this
question by randomizing between chemoradiation and
radioimmunotherapy following induction chemotherapy.
Until final results of this trial are available however, this
question cannot be reliably answered [36].
Long-term local control remains an issue in the age of
concomitant radiation schedules, targeted therapies and
induction chemotherapy. TPF was not overtly successful




end of treatment 1st f/u 2nd f/u
RChT RIT RChT RIT RChT RIT
dysphagia I 1 1 5 5 1
II 11 16 7 8
III 15 8 1 2 1
mucositis I 1 1 3 1
II 20 19 1
III 3 8
9 2
xerostomia I 4 7 11 1 1
II
laryngeal oedema 1 2
lymph oedema 1 1 3
weight loss (median, kg) 4 2 p = 0.01
range (kg) 0 - 14 0 - 9
PEG (pts) 27 21
CVK (pts) 3 1
toxicity CTC grade (if applicable) end of treatment 1st f/u 2nd f/u
RChT RIT RChT RIT RChT RIT
dysphagia I 1 1 5 5 1
II 11 16 7 8
III 15 8 1 2 1
mucositis I 1 1 3 1
II 20 19 1
III 3 8
9 2
xerostomia I 4 7 11 1 1
II
laryngeal oedema 1 2
lymph oedema 1 1 3
weight loss (median, kg) 4 2 p = 0.01
range (kg) 0 - 14 0 - 9
PEG (pts) 27 21
CVK (pts) 3 1
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cohort. In addition, radiochemotherapy and radioimmu-
notherapy do not show significant differences in local
control rates either in the study published by Caudell
[6] or in our patients. One potential treatment regimen,
which might prove beneficial in this context, is the
combination of platin-based radiochemotherapy and
immunotherapy currently under evaluation in the
RTOG 0522 [37] and also in our own REACH trial [38].
However, improvement by combination of these agents
may have limited effects and will only potentially be fea-
sible if toxicity rates are not significantly increased.
Since RChT and RIT show similar results with respect
to local control rates, further intensification of radio-
therapy needs to be explored to improve local control.
De-escalation of the systemic components (e.g. cetuxi-
mab only) may be feasible especially in regimens includ-
ing TPF induction and improve patient compliance.
Most of our patients did receive IMRT as simultaneous
integrated boost, is there still room to intensify radio-
therapy by altered fractionation in the age of IMRT?
The REACH trial [38] will try to address this issue by
investigating the combination of radiochemoimmu-
notherapy with carboplatin, 5-FU, and cetuximab and
intensity-modulated radiation therapy as concomitant
boost. In addition, particle therapy will shortly become
routinely available in some centres and offers the benefit
of extremely high conformality and increased relative
biological effectiveness. Therefore, integration of this
technique into standard radiochemo/radioimmunother-
apy regimens might result in higher control rates.
Potential gains warrant further exploration of this
hypothesis but need to be explored in active clinical
trials such as the TPF-C-HIT trial [39].
Conclusion
Even in patients with a compromised performance sta-
tus, modern combined-modality regimens lead to local
control and survival at rates comparable to large land-
mark trials. Observed acute and late toxicity rates are
low: persistent swallowing dysfunction is rare in our
cohort, no cervical plexopathies were observed.
No significant difference between radiochemotherapy
with carboplatin/5-FU and radioimmuntherapy with
cetuximab was observed. TPF induction therapy was
associated with improved progression-free as well as
overall survival. However, impact of TPF on locoregional
progression-free survival was only marginally positive
and not statistically significant, therefore novel radio-
therapeutic options for intensification of local treatment
should be explored.
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